NCT05483283 Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
| NCT ID | NCT05483283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois Chicago |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-01-18 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2023-01-18 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks
Eligibility Criteria
Inclusion Criteria: Aim 1 1. female biological sex 2. identification as Latina 3. one genetic risk factor (i.e., personal history of breast cancer or family history of breast or ovarian cancer) 4. one SDH risk factor, based on the American Cancer Society's definitions (e.g., perceived financial struggles; transportation difficulties; exposure to violence; housing challenges; social isolation/challenges) 5. 30+ years old, based on American Cancer Society (ACS) screening guidelines for high risk populations 6. No receipt of cancer genetic counseling AND no receipt of genetic testing Aim 2 1. female biological sex 2. referral from Latina Aim 1 participants 3. eligibility to obtain BC screenings, based on ACS guidelines (e.g., optional annual 4. screenings at 40-44 years old, recommended annual screenings at 45-54 years old, every other year screening at 55 and older) 5. self-report not attending Session #3 (as this will not be recorded by the staff) Aim 3 1. participant from Aim 1 or 2. participant from Aim 2 Exclusion Criteria: Aim 1 and Aim 2 Not meeting at least one of the inclusion criteria Aim 3 1. Not a participant from Aim 1 or 2. Not a participant from Aim 2
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05483283 clinical trial?
This trial is open to female participants only, aged 30 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05483283 currently recruiting?
Yes, NCT05483283 is actively recruiting participants. Contact the research team at ymolin2@uic.edu for enrollment information.
Where is the NCT05483283 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT05483283 clinical trial?
NCT05483283 is sponsored by University of Illinois Chicago. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.